capecitabine has been researched along with Hematologic Malignancies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fiebig, HH; Hendriks, HR; Kelter, G; Metz, T; Musch, A; Peille, AL; Vuaroqueaux, V; Weichert, L | 1 |
| Bilek, M; Bouskova, K; Fidlerova, J; Kleibl, Z; Kleiblova, P; Kormunda, S; Novotny, J; Sevcik, J | 1 |
2 other study(ies) available for capecitabine and Hematologic Malignancies
| Article | Year |
|---|---|
High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models.
Topics: Animals; Aurora Kinases; Capecitabine; Colorectal Neoplasms; Hematologic Neoplasms; Humans; Protein Kinase Inhibitors | 2023 |
Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Genetic Variation; Hematologic Neoplasms; Humans; Immunoenzyme Techniques; Male; Middle Aged; Mutation; Neoplasm Staging; Open Reading Frames; Polymerase Chain Reaction; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |